Time-dependent clearance of mycophenolic acid in renal transplant recipients

被引:71
|
作者
van Hest, Reinier M.
van Gelder, Teun
Bouw, Rene
Goggin, Timothy
Gordon, Robert
Mamelok, Richard D.
Mathot, Ron A.
机构
[1] Erasmus MC, Dept Hosp Pharm, Clin Pharmacol Unit, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[3] Roche Prod Ltd, Welwyn Garden City, Herts, England
[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[5] Roche Labs Inc, Nutley, NJ USA
[6] Mamelok Consulting, Palo Alto, CA USA
关键词
mycophenolic acid; pharmacokinetics; renal transplantation; time-dependent clearance;
D O I
10.1111/j.1365-2125.2006.02841.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Pharmacokinetic studies of the immunosuppressive compound mycophenolic acid (MPA) have shown a structural decrease in clearance (CL) over time after renal transplantation. The aim of this study was to characterize the time-dependent CL of MPA by means of a population pharmacokinetic meta-analysis, and to test whether it can be described by covariate effects. Methods One thousand eight hundred and ninety-four MPA concentration-time profiles from 468 renal transplant patients (range 1-9 profiles per patient) were analyzed retrospectively by nonlinear mixed effect modelling. Sampling occasions ranged from day 1-10 years after transplantation. Results The pharmacokinetics of MPA were described by a two-compartment model with time-lagged first order absorption, and a first-order term for time-dependent CL. The model predicted the mean CL to decrease from 35 l h(-1) (CV = 44%) in the first week after transplantation to 17 l h(-1) (CV = 38%) after 6 months. In a covariate model without a term for time-dependent CL, changes during the first 6 months after transplantation in creatinine clearance from 19 to 71 ml min(-1), in albumin concentration from 35 to 40 g l(-1), in haemoglobin from 9.7 to 12 g dl(-1) and in cyclosporin predose concentration from 225 to 100 ng ml(-1) corresponded with a decrease of CL from 32 to 19 l h(-1). Creatinine clearance, albumin concentration, haemoglobin and cyclosporin predose concentration explained, respectively, 19%, 12%, 4% and 3% of the within-patient variability in MPA CL. Conclusions By monitoring creatinine clearance, albumin concentration, haemoglobin and cyclosporin predose concentration, changes in MPA exposure over time can be predicted. Such information can be used to optimize therapy with mycophenolate mofetil.
引用
收藏
页码:741 / 752
页数:12
相关论文
共 50 条
  • [1] Explaining the Differences in Clearance of Mycophenolic Acid between Renal Transplant Recipients, Heamatopoietic Stemcell Transplant Recipients and Patients with Autoimmune Disease
    de Winter, Brenda C. M.
    Mathot, Ron A. A.
    Sombogaard, Ferdi
    Neumann, Irmgard
    van Hest, Reinier M.
    van Gelder, Teun
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 613 - 614
  • [2] Differences in Clearance of Mycophenolic Acid Among Renal Transplant Recipients, Hematopoietic Stem Cell Transplant Recipients, and Patients With Autoimmune Disease
    de Winter, Brenda C. M.
    Mathot, Ron A. A.
    Sombogaard, Ferdi
    Neumann, Irmgard
    van Hest, Reinier M.
    Doorduijn, Jeanette K.
    van Gelder, Teun
    THERAPEUTIC DRUG MONITORING, 2010, 32 (05) : 606 - 614
  • [3] Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients
    Reinier M. van Hest
    Teun van Gelder
    Arnold G. Vulto
    Ron A. A. Mathot
    Clinical Pharmacokinetics, 2005, 44 : 1083 - 1096
  • [4] Therapeutic monitoring of mycophenolic acid in renal transplant recipients
    Hübner, GI
    Eismann, R
    Sziegoleit, W
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (04) : R166 - R166
  • [5] Population pharmacokinetics of mycophenolic acid in renal transplant recipients
    van Hest, RM
    van Gelder, T
    Vulto, AG
    Mathot, RAA
    CLINICAL PHARMACOKINETICS, 2005, 44 (10) : 1083 - 1096
  • [6] Monitoring of mycophenolic acid in pediatric renal transplant recipients
    Armstrong, VW
    Shipkova, M
    Schütz, E
    Weber, L
    Tönshoff, B
    Oellerich, M
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1040 - 1043
  • [7] Mycophenolic acid population pharmacokinetics in Tunisian renal transplant recipients
    Gaies, E.
    El Jebari, H.
    Jebabli, N.
    Salouage, I.
    Trabelsi, S.
    Charfi, R.
    Lakhal, M.
    Klouz, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 70 - 70
  • [8] Plasma level monitoring of mycophenolic acid in renal transplant recipients
    Sarangi, S. C.
    Reeta, K. H.
    Agarwal, S. K.
    Guleria, S.
    Gupta, Y. K.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 52 - 52
  • [9] Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients
    Okamoto, M
    Wakabayashi, Y
    Higuchi, A
    Kadotani, Y
    Ogino, S
    Ushigome, H
    Akioka, K
    Kaihara, S
    Yoshimura, N
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 859 - 860
  • [10] Adverse effects of mycophenolic acid in renal transplant recipients: gender differences
    Ana Spasić
    Aleksandra Catić-Đorđević
    Radmila Veličković-Radovanović
    Nikola Stefanović
    Predrag Džodić
    Tatjana Cvetković
    International Journal of Clinical Pharmacy, 2019, 41 : 776 - 784